Lv5
840 积分 2021-02-07 加入
Cancer burden and control in China: landscape, trends and challenges
8天前
已完结
AI-driven discovery of GPNMB CAR T cells as a multi-cancer therapy
8天前
已完结
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
7个月前
已完结
Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity
9个月前
已完结
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma
10个月前
已完结
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma
10个月前
已完结
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
10个月前
已完结
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
10个月前
已完结
Trends in the development of cellular and gene therapy in China
11个月前
已完结
Bayesian dose escalation with overdose and underdose control utilizing all toxicities in Phase I/II clinical trials
11个月前
已完结
皖公网安备34019202002308
